Cancer BiologybioRxivPreprint
TFAP2A links drug resistance to antitumor immunity
Haiwei Mou, Veronika Yakovishina, Kristen M. DeRosa…·Meenhard Herlyn
This study identifies TFAP2A as a driver of BRAF/MEK inhibitor resistance and immunosuppression, showing its disruption enhances antitumor immunity and overcomes drug resistance.
DOI 10.64898/2026.07.08.735861